• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Analysis of influencing factors related to elevated serum troponin I level for COVID-19 patients in Yichang, China.中国宜昌新冠肺炎患者血清肌钙蛋白I水平升高相关影响因素分析
Cardiovasc Diagn Ther. 2020 Aug;10(4):678-686. doi: 10.21037/cdt-20-510.
2
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19.早期检测升高的心脏生物标志物以优化 COVID-19 患者的风险分层。
Heart. 2020 Oct;106(19):1512-1518. doi: 10.1136/heartjnl-2020-317322. Epub 2020 Aug 14.
3
Elevated troponin I levels but not low grade chronic inflammation is associated with cardiac-specific mortality in stable hemodialysis patients.在稳定的血液透析患者中,肌钙蛋白I水平升高而非低度慢性炎症与心脏特异性死亡率相关。
BMC Nephrol. 2013 Nov 9;14:247. doi: 10.1186/1471-2369-14-247.
4
Analysis of Age-Specific Predictors of Mortality in Patients with Coronavirus Disease 2019.分析 2019 冠状病毒病患者死亡率的年龄特异性预测因素。
Niger J Clin Pract. 2024 Feb 1;27(2):244-251. doi: 10.4103/njcp.njcp_507_23. Epub 2024 Feb 26.
5
What does elevated high-sensitive troponin I in stroke patients mean: concomitant acute myocardial infarction or a marker for high-risk patients?脑卒中患者高敏肌钙蛋白 I 升高意味着什么:合并急性心肌梗死还是高危患者的标志物?
Cerebrovasc Dis. 2013;36(3):211-7. doi: 10.1159/000353875. Epub 2013 Oct 12.
6
Association between cardiac troponin I and mortality in patients with COVID-19.新型冠状病毒肺炎患者心肌肌钙蛋白 I 与死亡率的关系。
Biomarkers. 2020 Dec;25(8):634-640. doi: 10.1080/1354750X.2020.1831609. Epub 2020 Nov 24.
7
Predictive role of clinical features in patients with coronavirus disease 2019 for severe disease.2019冠状病毒病患者临床特征对重症疾病的预测作用
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 May 28;45(5):536-541. doi: 10.11817/j.issn.1672-7347.2020.200384.
8
Clinical characteristics and risk factors for in-hospital mortality of lung cancer patients with COVID-19: A multicenter, retrospective, cohort study.COVID-19 肺癌患者住院死亡率的临床特征和危险因素:一项多中心、回顾性、队列研究。
Thorac Cancer. 2021 Jan;12(1):57-65. doi: 10.1111/1759-7714.13710. Epub 2020 Nov 3.
9
Laboratory predictors of death from coronavirus disease 2019 (COVID-19) in the area of Valcamonica, Italy.意大利瓦尔卡莫尼卡地区预测 2019 年冠状病毒病(COVID-19)死亡的实验室指标。
Clin Chem Lab Med. 2020 Jun 25;58(7):1100-1105. doi: 10.1515/cclm-2020-0459.
10
Changes and significance of serum troponin in trauma patients: A retrospective study in a level I trauma center.创伤患者血清肌钙蛋白的变化及其意义:一项在一级创伤中心进行的回顾性研究。
World J Emerg Med. 2022;13(1):27-31. doi: 10.5847/wjem.j.1920-8642.2022.016.

引用本文的文献

1
Disability in mitochondrial aerobic metabolism and Mg transport: linking biomarkers and mechanisms of ischemic heart disease to diesel particulate matter exposure.线粒体有氧代谢和镁转运功能障碍:将缺血性心脏病的生物标志物和机制与柴油颗粒物暴露联系起来。
BMC Med. 2025 Jul 1;23(1):379. doi: 10.1186/s12916-025-04212-w.
2
Dysbiosis: An Indicator of COVID-19 Severity in Critically Ill Patients.肠道菌群失调:危重症 COVID-19 患者病情严重的指标。
Int J Mol Sci. 2022 Dec 13;23(24):15808. doi: 10.3390/ijms232415808.
3
Myocardial injuries among patients with COVID-19: a systematic review.新型冠状病毒肺炎患者的心肌损伤:一项系统评价
Infez Med. 2021 Sep 10;29(3):345-354. doi: 10.53854/liim-2903-5. eCollection 2021.
4
Subclinical myocardial injury, coagulopathy, and inflammation in COVID-19: A meta-analysis of 41,013 hospitalized patients.新型冠状病毒肺炎中的亚临床心肌损伤、凝血病和炎症:对41013例住院患者的荟萃分析
Int J Cardiol Heart Vasc. 2022 Jun;40:100950. doi: 10.1016/j.ijcha.2021.100950. Epub 2022 Jan 4.
5
Cardiovascular Disease Complicating COVID-19 in the Elderly.老年 COVID-19 合并心血管疾病。
Medicina (Kaunas). 2021 Aug 17;57(8):833. doi: 10.3390/medicina57080833.
6
No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not.在接受磷酸氯喹治疗和未接受磷酸氯喹治疗的 COVID-19 患者中,缺血性心脏损伤和心力衰竭的生物标志物没有差异。
PLoS One. 2021 Aug 16;16(8):e0256035. doi: 10.1371/journal.pone.0256035. eCollection 2021.

本文引用的文献

1
Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019.严重 2019 冠状病毒病患者心肌损伤的特征及临床意义。
Eur Heart J. 2020 Jun 7;41(22):2070-2079. doi: 10.1093/eurheartj/ehaa408.
2
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).COVID-19 患者的致命结局对心血管的影响。
JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
3
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.新冠肺炎住院患者中心脏损伤与死亡的相关性研究:中国武汉。
JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
4
Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.心血管考虑因素在 COVID-19 大流行期间的患者、医护人员和卫生系统。
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371. doi: 10.1016/j.jacc.2020.03.031. Epub 2020 Mar 19.
5
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
6
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
7
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges.严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)和 2019 年冠状病毒病(COVID-19):疫情和挑战。
Int J Antimicrob Agents. 2020 Mar;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924. Epub 2020 Feb 17.
8
[The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China].[中国2019新型冠状病毒病(COVID-19)疫情的流行病学特征]
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003.
9
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
10
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.新型冠状病毒在武汉持续爆发中的进化及其刺突蛋白对人类传播风险的建模。
Sci China Life Sci. 2020 Mar;63(3):457-460. doi: 10.1007/s11427-020-1637-5. Epub 2020 Jan 21.

中国宜昌新冠肺炎患者血清肌钙蛋白I水平升高相关影响因素分析

Analysis of influencing factors related to elevated serum troponin I level for COVID-19 patients in Yichang, China.

作者信息

Fan Zhi-Xing, Yang Jun, Zhang Jing, He Chao, Wu Hui, Yang Chao-Jun, Zheng Tao, Ma Cong, Xiang Zu-Jin, Zhai Yu-Hong, Jiang Jing, Qiu Shao-Qin, Yang Jian

机构信息

Department of Cardiology, the First College of Clinical Medical Sciences, China Three Gorges University & Yichang Central People's Hospital, Yichang, China.

Central Laboratory, the First College of Clinical Medical Sciences, China Three Gorges University & Yichang Central People's Hospital, Yichang, China.

出版信息

Cardiovasc Diagn Ther. 2020 Aug;10(4):678-686. doi: 10.21037/cdt-20-510.

DOI:10.21037/cdt-20-510
PMID:32968624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7487375/
Abstract

BACKGROUND

Cardiac injury is a common condition among hospitalized coronavirus disease 2019 (COVID-19) patients, and is associated with a higher risk of mortality. However, the mechanism of myocardial injury in COVID-19 remains unclear. In this retrospective study, we compared the clinical characteristics of COVID-19 patients with different troponin I (TnI) levels during hospitalization to provide a clinical reference for the identification of those at high-risk.

METHODS

In total, 218 patients diagnosed with COVID-19 in Yichang Central People's Hospital and Yichang Third People's Hospital between January 23 and February 19, 2020 were initially included. Of these patients, 89 underwent TnI testing during hospitalization and were finally included in the study. The medical history, clinical signs and symptoms at the time of admission, and laboratory test results were recorded. The patients were assigned to the normal TnI group (TnI <0.01 µg/L; n=67) or the elevated TnI group (TnI >0.01 µg/L; n=22).

RESULTS

The incidence of elevated TnI in our patient cohort was 24.7%. There were significant differences between the two groups in the following factors: history of coronary heart disease (CHD), age, lymphocyte count, prothrombin time (PT), activated partial thromboplastin time (APTT), and levels of interleukin (IL)-6, C-reactive protein (CRP), myoglobin (MYO), lactate dehydrogenase (LDH), and albumin (all P<0.05). Binary logistic analysis showed that a history of CHD, age, lymphocyte count, IL-6, APTT, and MYO were influencing factors of elevated serum TnI.

CONCLUSIONS

A history of CHD, advanced age, decreased lymphocyte count, increased IL-6, increased MYO, and prolonged APTT were independent influencing factors of elevated TnI in COVID-19 patients. COVID-19 patients with these characteristics are prone to myocardial injury.

摘要

背景

心脏损伤是2019冠状病毒病(COVID-19)住院患者中的常见情况,且与较高的死亡风险相关。然而,COVID-19中心肌损伤的机制仍不清楚。在这项回顾性研究中,我们比较了COVID-19患者住院期间不同肌钙蛋白I(TnI)水平的临床特征,以为识别高危患者提供临床参考。

方法

最初纳入2020年1月23日至2月19日期间在宜昌市中心人民医院和宜昌市第三人民医院诊断为COVID-19的218例患者。其中,89例患者在住院期间接受了TnI检测,最终纳入研究。记录病史、入院时的临床体征和症状以及实验室检查结果。将患者分为TnI正常组(TnI<0.01μg/L;n=67)或TnI升高组(TnI>0.01μg/L;n=22)。

结果

我们的患者队列中TnI升高的发生率为24.7%。两组在以下因素方面存在显著差异:冠心病(CHD)病史、年龄、淋巴细胞计数、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)以及白细胞介素(IL)-6、C反应蛋白(CRP)、肌红蛋白(MYO)、乳酸脱氢酶(LDH)和白蛋白水平(均P<0.05)。二元逻辑回归分析显示,CHD病史、年龄、淋巴细胞计数、IL-6、APTT和MYO是血清TnI升高的影响因素。

结论

CHD病史、高龄、淋巴细胞计数减少、IL-6升高、MYO升高和APTT延长是COVID-19患者TnI升高的独立影响因素。具有这些特征的COVID-19患者易发生心肌损伤。